产业端催化不断，脑机接口正当时 20260105 摘要 全球脑机接口市场规模在 2024 年已达 26.2 亿美元，预计 2025 至 2034 年复合增长率为 17.4%；中国市场规模相对较小，预计 2028 年 后突破 60 亿美元，增长潜力巨大。 Neuralink 公司在侵入式脑机接口领域取得进展，N1 芯片拥有 1,024 个电极信号采集点，计划提升至 3,000 个以上，并采用手术机器人进行 精确植入，但长期材料安全性仍是挑战。 非侵入式脑机接口技术门槛较低，多家公司已获二类医疗器械证书并商 业化销售，主要应用于医院康复科等，收费标准提升至 900 多元，已有 8 省份出台收费目录，增加医院收入并提高康复效率。 国家政策高度重视脑机接口行业，纳入"十五五"规划并成立专项基金， 医保局单独立项收费报销，创新审评绿色通道加速临床试验，有望在未 来几年实现更多人体临床试验和商业化。 国内脑机接口技术在电极数量上已基本对标国际水平，供应链以国内为 主，关键节点包括政策落地、一级公司进入临床试验、持续融资及上市， 非侵入式产品预计 2026 年商业化，侵入式产品有望在临床试验中取得 进展。 Q&A 脑机接口 ...

Summary of Key Points from the Conference Call on Medical Devices and Brain-Computer Interfaces Industry Overview - The medical device sector is expected to see improvements in bidding processes in 2025, leading to stable or accelerated revenue growth for leading companies like United Imaging and Mindray in 2026. The new equipment update projects are set to be implemented in Q3 2025, suggesting a "front low, back high" growth pattern for next year's performance [1][2][3]. - The high-value consumables sector is anticipated to recover in valuation and performance due to optimized procurement policies, although the timing of performance turning points may vary among companies [1][3]. - The IVD (in vitro diagnostics) sector is expected to see a reduction in the impact of procurement policies by 2026, with companies like Mindray, New Industries, and United Imaging benefiting from enhanced product competitiveness and international market expansion [1][3]. Key Companies and Their Prospects - **Mindray Medical**: Currently at a long-cycle turning point, with positive revenue growth expected to continue. The company is transitioning from a device-centric model to focus more on IVD and other business lines, aiming to increase its overseas market share from over 40% to nearly 60% [1][7][8]. - **New Industries**: The company has seen its overseas business share rise to over 40%, maintaining a growth rate of 25%-30% annually, with a projected growth rate of 20%-25% for 2025. The gross margin for overseas revenue is also improving, from 50% in 2023 to 68% in the first half of 2025 [2][9]. - **Huatai Medical**: Expected to achieve significant revenue and net profit growth in 2026, particularly in its electrophysiology business, which is projected to see a substantial increase in procedure volumes due to procurement policy changes [1][14]. Investment Opportunities in Brain-Computer Interfaces (BCI) - The BCI sector is gaining traction as a significant investment area, with companies like Neuralink conducting clinical trials and advancing their technology. Domestic firms such as Xiangyu Medical and Sanbo Neuroscience are expected to accelerate their clinical trials and achieve more results in 2026 [2][4][18]. - Notable companies in the BCI field include **Micron Medical**, which has established a brain-machine research institute and reported a revenue of 760 million CNY in 2024, and **New Wei Medical**, which has turned profitable and is expected to see significant profit growth in the coming years [11][20]. Market Characteristics and Trends - The Hong Kong medical device sector is characterized by strong innovation, with many companies reaching a breakeven point and entering a phase of rapid profit release. Companies like MicroPort and MicroPort Robotics are highlighted as long-term investment opportunities [2][12]. - The low-value consumables sector is expected to grow steadily domestically, while international expansion will depend on the progress of domestic companies' overseas production capacity and changes in tariffs [17]. Conclusion - The medical device and BCI sectors are poised for recovery and growth, driven by policy improvements, strategic company adjustments, and international market expansion. Investors are encouraged to focus on companies with strong fundamentals and rapid commercialization processes, such as Mindray, Huatai Medical, and emerging players in the BCI space [2][24].

脑机接口产业最新动态电话会议 20260105 摘要 中国脑机接口产业在政策支持下快速发展，国家设立专项基金，从 2024 年的 30 亿元增至 2025 年的 700 亿元，并有多部门联合发文支 持，为产业从 0 到 1 的突破提供保障，投资者应关注受益于政策的企业。 脑机接口技术应用广泛，涵盖医疗健康、消费电子和娱乐互动等领域。 医疗健康是短期核心应用方向，包括精神疾病治疗等，而消费电子如情 绪监测耳机和娱乐互动等 C 端应用场景潜力巨大。 市场对脑机接口行业的定价逻辑已转变为注重新质生产力核心资产的战 略性站位，愿意为具备广阔护城河及高技术壁垒的远期行业支付较高估 值溢价，不再仅关注短期 EPS。 脑机接口产业链包括上游（芯片、采集设备）、中游（软硬件转化）和 下游（医疗、娱乐）。投资者应关注具备核心技术能力的公司，特别是 电极材料、芯片、算法和行业应用整合能力。 不同类型的脑机接口产品处于不同发展阶段，非侵入式产品已实现小规 模商业化，而半侵入式、侵入式产品仍处于临床试验阶段，投资者应重 点考虑不同类型产品之间的壁垒差异。 Q&A 脑机接口技术目前在全球范围内的发展状况如何？ 脑机接口技术近年来取得了 ...

Core Viewpoint - The "brain-computer interface" (BCI) concept is gaining significant attention in the A-share market, particularly following Elon Musk's announcement regarding Neuralink's plans for large-scale production of BCI devices in 2026 [1][2]. Industry Summary - The BCI sector is recognized as a rapidly developing industry, with approximately 11 provinces and cities in China having established related charging standards, spurred by the National Healthcare Security Administration's guidance on BCI rehabilitation fees [2]. - The "14th Five-Year Plan" has identified BCI as one of the six key future industries for development [3]. Company Summary - Tom Cat (300459.SZ) experienced a notable stock increase of 16.34% on January 5, 2026, following its involvement in the BCI field through its subsidiary, Shanghai Jinke Tom Cat Life Technology Co., Ltd., which focuses on BCI research and applications [4][5]. - The company has filed multiple patents related to BCI technologies, including flexible sleep monitoring devices and wireless brain stimulation systems [5]. - Despite its involvement in BCI, Tom Cat has a total of 37 concepts, including cloud gaming, metaverse, artificial intelligence, and more [6]. - Currently, Tom Cat does not have any formal commercialized products in the BCI sector, focusing instead on technology accumulation and business exploration [7]. - The company has faced financial challenges, reporting a net loss of 865 million yuan in 2023 and a projected loss of 859 million yuan in 2024 [9][10]. - Historical stock performance shows significant volatility, with a maximum increase of 210.49% from late 2022 to mid-2025, followed by a substantial decline of 66.53% [11][12]. - The company has incurred substantial goodwill impairment losses, totaling 2.611 billion yuan in 2019 and over 1.7 billion yuan in 2023 and 2024 [12].

Group 1 - The core viewpoint of the article is that the recent stock market rally is driven by the return of liquidity, with significant movements in cryptocurrencies indicating a shift towards high-yield assets [3][5] - On January 5, 2023, the Shanghai Composite Index regained the 4000-point mark, and the ChiNext Index rose over 2%, reflecting a positive market sentiment fueled by policy support for sectors like brain-computer interfaces [3][5] - The decline in short-term Shibor rates, such as the 7-day rate dropping to 1.423%, has made capital cheaper, encouraging a shift from stable assets like government bonds to the stock market [3][5] Group 2 - Despite the overall market strength, many investors are struggling to profit, as the rapid rotation of sectors and stocks makes it difficult to capture gains [3][5] - The article highlights a specific stock that experienced a 50% increase over three months, but its volatile price movements led many investors to sell at a loss during corrections [3][5] - The increasing dominance of institutional investors, who now account for over 50% of market activity, has changed the dynamics of trading, making it a game of "institution vs. retail" [7][10] Group 3 - The article discusses the concept of "institutional shaking," where institutions manipulate stock prices to eliminate weaker hands, causing retail investors to panic and sell [5][8] - It emphasizes the importance of understanding the underlying behaviors of capital flows, suggesting that using quantitative data can help investors identify true market trends and avoid being misled by price fluctuations [10][11] - The article advocates for a shift in investment strategy, encouraging investors to adopt quantitative thinking to better navigate the current market environment dominated by institutional players [10][11]

周一，脑再生科技(RGC.US)盘前大涨超21%，报25.04美元。值得注意的是，日内A股、港股脑机接口 板块分别大涨13%、12%。消息面上，马斯克"量产预告"催化，导致脑机接口概念大爆发。据悉，脑再 生科技与脑机接口的关系，可以理解为医学上"修复硬件"与"建立连接"的上下游关系。当脑机接口概念 受市场热捧时，作为其基础和延伸的脑再生技术，因共享"大脑科技"这一宏大叙事，而容易产生产业链 联动上涨的效应。 ...

Core Viewpoint - Brain Rejuvenation Technology (RGC.US) experienced a pre-market surge of over 21%, reaching $25.04, driven by Elon Musk's announcement regarding mass production, which catalyzed a significant rally in the brain-computer interface sector [1] Industry Summary - The A-share and Hong Kong stock markets saw the brain-computer interface sector rise by 13% and 12% respectively, indicating strong market interest [1] - The relationship between Brain Rejuvenation Technology and brain-computer interfaces can be understood as an upstream and downstream connection in the medical field, where "repairing hardware" and "establishing connections" are interlinked [1] - The popularity of brain-computer interface concepts in the market has led to a chain reaction, causing the associated brain rejuvenation technologies to benefit from the overarching narrative of "brain technology" [1]

Core Viewpoint - The A-share market experienced a strong start to 2026, with major indices rising significantly, indicating a bullish sentiment among investors and potential for continued growth throughout the year [1][2][4]. Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to close at 4023.42 points, while the ChiNext Index increased by 2.85% to 3294.55 points [2]. - The total trading volume in the Shanghai and Shenzhen markets reached 2.55 trillion yuan, a substantial increase of 501.1 billion yuan compared to the previous trading day [2]. Sector Highlights - The brain-computer interface sector led the market, with over 30 stocks hitting the daily limit [1][2]. - The commercial aerospace sector also showed significant activity, contributing to the overall market momentum [1][2]. Investor Sentiment - Private equity firms view the strong opening day as a positive signal, with historical data suggesting that years starting with a market rise have a greater than 60% chance of ending positively [2]. - The recent increase in investor sentiment is attributed to strong performances in technology and emerging industries, particularly AI and semiconductors [3][4]. Investment Strategies - Investment strategies for 2026 focus on structural opportunities driven by the appreciation of the yuan, cyclical recovery, globalization, supply-demand improvements, and technological innovation [6][7]. - Key areas of interest include the AI industry chain, robotics, commercial aerospace, brain-computer interfaces, and domestic substitution [6][7]. Market Outlook - The overall outlook for 2026 suggests a continuation of the bull market, with a shift in driving factors from liquidity to fundamentals [7]. - Investors are advised to balance their portfolios while being mindful of market volatility and the pace of economic recovery [7].

Market Overview - A-shares showed strong performance with major indices achieving gains at the start of 2026, with the Shanghai Composite Index returning to 4000 points [1] - The Hong Kong stock market also experienced slight gains despite geopolitical tensions arising from the U.S. military action in Venezuela [1] Geopolitical Impact - The U.S. military operation in Venezuela, resulting in the capture of President Maduro, is seen as a strategic move by President Trump to assert U.S. influence in South America and potentially seize Venezuelan oil resources [1][2] - This event is expected to have negative repercussions for stability in South America and could impact Chinese investments in Venezuela, which amount to over $60 billion [2] Insurance Industry - The insurance sector experienced a strong start to the year, with leading companies reporting new policy premium growth rates between 40% and 60% [3] - The influx of funds into insurance is attributed to the maturity of significant deposits, with insurance rates being more attractive than some bank deposits [3] Brain-Computer Interface Market - Neuralink, led by Elon Musk, plans to begin large-scale production of brain-computer interface devices by 2026, with the global market projected to reach approximately $12.4 billion by 2034 [3] - Companies in the brain-computer interface sector saw significant stock price increases, with some rising nearly 40% [3] Pharmaceutical Industry - The 44th J.P. Morgan Healthcare Conference is set to attract over 8,000 participants, highlighting the growing interest in the pharmaceutical sector [4] - In 2025, China approved 76 innovative drugs, significantly surpassing the previous year's total, and the total value of drug licensing transactions exceeded $130 billion [4] Robotics Sector - U Tree Technology clarified reports regarding its IPO status, while home robotics company Woan Robotics announced plans to launch a humanoid household robot in January 2026 [5] - Woan Robotics has shown a compound annual growth rate of 49% in revenue over the past three years, leading to a stock price increase of over 19% [5] Semiconductor Industry - The National Integrated Circuit Fund increased its stake in SMIC from 4.79% to 9.25%, indicating strong support for domestic semiconductor development [6] - Companies in the semiconductor sector, including SMIC and Huahong Semiconductor, experienced stock price increases [6] Nuclear Energy Sector - Tokyo Electric Power Company plans to restart the Kashiwazaki-Kariwa Nuclear Power Plant, which may impact uranium supply dynamics [7] - Companies involved in uranium mining, such as CGN Mining, saw stock price increases due to expectations of tighter supply [7] Real Estate Market - A recent article emphasized the importance of stabilizing the real estate market, with new tax policies aimed at reducing transaction costs for home sales [8] - The reduction of capital gains tax on property sales is expected to stimulate demand for new homes and facilitate market liquidity [8] Construction Machinery Industry - Zoomlion reported strong domestic and international sales growth, with a projected increase in sales of construction machinery [9] - The company is expanding its presence in the global market and has plans for significant investments in research and development [10][11]

Core Viewpoint - The brain-machine interface (BMI) industry is transitioning from experimental research to commercial viability, with Neuralink's announcement of mass production in 2026 marking a significant turning point for the sector [1][3]. Group 1: Industry Developments - Neuralink, founded by Elon Musk in 2016, aims to develop high-bandwidth, low-invasiveness brain-machine interface technology to treat neurological diseases and facilitate human-AI coexistence [3]. - As of January 2024, Neuralink completed its first human implantation of a BMI device, with 12 individuals having received the device by September 2025, accumulating over 15,000 hours of usage [3][4]. - The company has demonstrated that clinical trial participants can control devices such as robotic arms and play video games using only their brain signals [4]. Group 2: Market Expectations - The global brain-machine interface market is projected to grow to approximately $12.4 billion by 2034, indicating strong commercial potential [5]. - Neuralink raised over $650 million in 2025 for factory construction and technology scaling, with a post-money valuation of around $9 billion as of June 2025 [5]. - The company plans to expand its technology capabilities, including direct language decoding and visual restoration, with milestones set for 2025 through 2028 [5]. Group 3: Technological Challenges - Despite advancements, the invasive nature of BMIs presents challenges related to biocompatibility and long-term stability, which need to be addressed for widespread adoption [1][6]. - The commercialization of BMIs requires overcoming significant hurdles, including lengthy validation processes and substantial funding needs, as highlighted by industry experts [7][8]. - Competitors like Synchron predict that medical applications of BMIs may take 3 to 5 years for approval, while consumer-grade devices could take 15 to 20 years to become viable [8].